New Delhi: The first phase of human trials for the Covid vaccine developed by Bharat biotech has already started. While there are claims of people getting infected in clusters, the news of human trials of the new vaccine holds significance. 15 July onwards, the human trial of the vaccine has started on 375 self-help volunteers, informed the sources. ICMR has nominated 12 organisations including AIIMS in Delhi. In the first phase, 375 people are to be part of the human trial, which include 100 from AIIMS.
The Covaxin has been developed by joint efforts of Bharat Biotech from Hyderabad and Indian Council of Medical Research (ICMR). Moreover, CDSCO granted permission to conduct human trials after the examination of this vaccine. Accordingly, this trial is going to be conducted in 12 hospitals across various Indian states. These hospitals include AIIMS- Delhi, AIIMS- Patna. Besides, only well and healthy people, who are between the age group of 18-55 will be tested with this vaccine.
The government has granted permission to Bharat Biotech to conduct these trials in three phases. About seven companies across the nation are involved in the production of this vaccine. The volunteer would be dosed with the first round of vaccine and its effects would be examined. Following this, the second dose would be given 14 days later to distinguish the improvements. Moreover, during this span, the side effects of this vaccine will also be observed if any.
Furthermore, the Chairman and MD of Bharat Biotech, Dr Krishna Ella, asserted that they are prepared to create 20 crore doses if the trials are successful. Meanwhile, three people were dosed with this vaccine in Rohtak, Haryana. Experts asserted that the side effects of that no side effects of that vaccine were observed. However, the effects of the vaccine will be examined hereafter as well. Moreover, the reports of these trials will be sent to ICMR.